Evidence map›Paper›PMID 36602380›Full record

ArticleInfection and immunity2023

MRSA Isolates from Patients with Persistent Bacteremia Generate Nonstable Small Colony Variants

Thiago Fauerharmel-Nunes, Ronald S Flannagan, Mariya I Goncheva, Arnold S Bayer, Vance G Fowler, Liana C Chan, Michael R Yeaman, Yan Q Xiong, David E Heinrichs

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Persistence ofMicroorganisms · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Thiago Fauerharmel-NunesDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Ronald S FlannaganDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0002-3263-2227
Mariya I GonchevaDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0001-9796-6060
Arnold S BayerThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California, USA.
Vance G FowlerDuke University Medical Center, Durham, North Carolina, USA.
Liana C ChanThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California, USA.
Michael R YeamanThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California, USA.
Yan Q XiongThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California, USA.
David E HeinrichsDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0002-7217-2456
University of California, Los Angeles · USWestern University · CADuke Medical Center · US

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
HLA Fine Mapping to Elucidate S. aureus SusceptibilityR01AI165671 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G., SCOTT, WILLIAM K · 2021 to 2025
$3.8M
Mechanisms and Circumvention of Daptomycin Resistance in Streptococcus mitisR01AI130056 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI BAYER, ARNOLD S · 2018 to 2022
$2.4M
The role of purine biosynthesis and stringent response in persistent MRSA endovascular infectionsR01AI139244 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI XIONG, YAN Q. · 2019 to 2023
$2.2M
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical TranslatabilityR01AI146078 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI XIONG, YAN Q. · 2019 to 2023
$1.9M
NCATS NIH HHS KL2 TR001882NIAID NIH HHS R01 AI130056NIAID NIH HHS R01 AI139244NIAID NIH HHS R01 AI146078NIAID NIH HHS R01 AI165671
6 · The paper itself

Abstract

Staphylococcus aureus (especially methicillin-resistant S. aureus [MRSA]) is frequently associated with persistent bacteremia (PB) during vancomycin therapy despite consistent susceptibility

Indexed as

BacteremiaMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnti-Bacterial AgentsEndothelial CellsHumansMacrophagesMethicillin ResistanceMicrobial Sensitivity TestsVancomycinAnti-Bacterial AgentsVancomycinMRSApersistent bacteremiaresolving bacteremiavancomycin

Identifiers

PMID36602380
PMCPMC9872686
OpenAlexW4313546100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.